Specializing in predictive solutions for pharmaceutical research, last week the Lyon-based SME unveiled an ambitious but costly strategic plan to 2028, based on organic growth. Since then, the share price has fallen by almost 15 %. Small and mid caps are still struggling. Expected for months, or even...